Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLC

Giorgio Scagliotti, MD, PhD
Published: Tuesday, Oct 11, 2016



Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

The study compared the efficacy and safety of ceritinib (Zykadia) to standard second-line chemotherapy (pemetrexed or docetaxel) in patients with advanced ALK+ non-small cell lung cancer (NSCLC) who progressed on prior crizotinib (Xalkori) and 1 or 2 prior regimens of chemotherapy.

According to Scagliotti, the results of the study were both clinically and statistically meaningful. Median progression-free survival was significantly improved with ceritinib compared to chemotherapy (5.4 vs 1.6 months).


Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

The study compared the efficacy and safety of ceritinib (Zykadia) to standard second-line chemotherapy (pemetrexed or docetaxel) in patients with advanced ALK+ non-small cell lung cancer (NSCLC) who progressed on prior crizotinib (Xalkori) and 1 or 2 prior regimens of chemotherapy.

According to Scagliotti, the results of the study were both clinically and statistically meaningful. Median progression-free survival was significantly improved with ceritinib compared to chemotherapy (5.4 vs 1.6 months).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x